Etravirine, a second generation NNRTI, is a weak inducer of CYP3A and a weak inhibitor of P-glycoprotein and constitutes a valuable option for concomitant use with BEACOPP chemotherapy for advanced HD (Kurz et al., 2015). Here, CYP3A4 is linked to Huntington disease.